Last reviewed · How we verify

Fecal Microbial Transplantation — Competitive Intelligence Brief

Fecal Microbial Transplantation (Fecal Microbial Transplantation) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biotherapeutic microbiota therapeutic. Area: Gastroenterology / Infectious Disease / Immunology.

phase 3 Biotherapeutic microbiota therapeutic Gastroenterology / Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

Fecal Microbial Transplantation (Fecal Microbial Transplantation) — ProgenaBiome. Fecal microbial transplantation (FMT) restores a healthy gut microbiome by transferring bacterial communities from a healthy donor to a patient with dysbiosis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fecal Microbial Transplantation TARGET Fecal Microbial Transplantation ProgenaBiome phase 3 Biotherapeutic microbiota therapeutic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biotherapeutic microbiota therapeutic class)

  1. ProgenaBiome · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fecal Microbial Transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/fecal-microbial-transplantation. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing